To date, the most encouraging clinical data that supports the importance of CTLA-4 pathway in AML comes from a phase I trial exploring the use of ipilimumab in patients with hematological malignancies relapsing post allo-HSCT. Here, CTLA4 is linked to acute myeloid leukemia.